Decreased mitochondrial respiration in

aneurysmal aortas of Fibulin-4 mutant mice is

linked to PGC1A regulation by van der Pluijm, I. et al.
This is a repository copy of Decreased mitochondrial respiration in aneurysmal aortas of 
Fibulin-4 mutant mice is linked to PGC1A regulation.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/133573/
Version: Published Version
Article:
van der Pluijm, I., Burger, J., van Heijningen, P.M. et al. (21 more authors) (2018) 
Decreased mitochondrial respiration in aneurysmal aortas of Fibulin-4 mutant mice is 
linked to PGC1A regulation. Cardiovascular Research. cvy150. ISSN 0008-6363 
https://doi.org/10.1093/cvr/cvy150
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) 
licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new 
works must also acknowledge the authors and be non-commercial. You don’t have to license any derivative 
works on the same terms. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Decreasedmitochondrial respiration in
aneurysmal aortas of Fibulin-4mutantmice is
linked to PGC1A regulation
Ingrid van der Pluijm1,2*, Joyce Burger2,3¶, Paula M. van Heijningen2¶, Arne IJpma4,
Nicole van Vliet2, Chiara Milanese2, Kees Schoonderwoerd3, Willem Sluiter2,
Lea-Jeanne Ringuette5, Dirk H.W. Dekkers6, Ivo Que7, Erik L. Kaijzel7, Luuk te Riet1,8,
Elena G. MacFarlane9, Devashish Das2†, Reinier van der Linden10‡, Marcel Vermeij11,
Jeroen A. Demmers6, Pier G. Mastroberardino2, Elaine C. Davis5,
Hiromi Yanagisawa12, Harry C. Dietz9,13,14, Roland Kanaar15,16, and
Jeroen Essers1,15,16*
1Department of Vascular Surgery, Erasmus MC, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands; 2Department of Molecular Genetics, Erasmus MC, Wytemaweg 80, 3015 CN
Rotterdam, The Netherlands; 3Department of Clinical Genetics, Erasmus MC, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands; 4Clinical Bioinformatics Unit, Department of Pathology,
Erasmus MC, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands; 5Department of Anatomy and Cell Biology, McGill University, 3640 Rue University, Montre´al, QC H3A 0C7, Canada;
6Proteomics Center, Erasmus MC, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands; 7Department of Radiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The
Netherlands; 8Department of Pharmacology, Erasmus MC, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands; 9Department of Surgery, McKusick-Nathans Institute of Genetic Medicine,
Johns Hopkins University School of Medicine, 733 N Broadway, Baltimore, MD 21205, USA; 10Stem cell Institute, Erasmus MC, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands;
11Department of Pathology, Erasmus MC, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands; 12Life Science Center, Tsukuba Advanced Research Alliance, University of Tsukuba, 1-1-1
Tennodai, Tsukuba, Ibaraki, 305-8577 Japan; 13Institute of Genetic Medicine, Johns Hopkins University School of Medicine, 733 N Broadway, Baltimore, MD 21205, USA; 14Division of Pediatric
Cardiology, Department of Pediatrics, and Department of Medicine, Johns Hopkins University School of Medicine, 733 N Broadway, Baltimore, MD 21205, USA; 15Department of Radiation
Oncology, Erasmus MC, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands; and 16Department of Molecular Genetics, Oncode Institute, Erasmus MC, Rotterdan, The Netherlands
Received 7 July 2017; revised 26 September 2017; editorial decision 7 June 2018; accepted 19 June 2018
Time for primary review: 86 days
Aim Thoracic aortic aneurysms are a life-threatening condition often diagnosed too late. To discover novel robust bio-
markers, we aimed to better understand the molecular mechanisms underlying aneurysm formation.
....................................................................................................................................................................................................
Methods
and results
In Fibulin-4R/R mice, the extracellular matrix protein Fibulin-4 is 4-fold reduced, resulting in progressive ascending aneu-
rysm formation and early death around 3 months of age. We performed proteomics and genomics studies on Fibulin-4R/R
mouse aortas. Intriguingly, we observed alterations in mitochondrial protein composition in Fibulin-4R/R aortas.
Consistently, functional studies in Fibulin-4R/R vascular smooth muscle cells (VSMCs) revealed lower oxygen consumption
rates, but increased acidification rates. Yet, mitochondria in Fibulin-4R/R VSMCs showed no aberrant cytoplasmic localiza-
tion. We found similar reduced mitochondrial respiration in Tgfbr-1M318R/þ VSMCs, a mouse model for Loeys-Dietz syn-
drome (LDS). Interestingly, also human fibroblasts from Marfan (FBN1) and LDS (TGFBR2 and SMAD3) patients showed
lower oxygen consumption. While individual mitochondrial Complexes I–V activities were unaltered in Fibulin-4R/R heart
and muscle, these tissues showed similar decreased oxygen consumption. Furthermore, aortas of aneurysmal Fibulin-4R/R
mice displayed increased reactive oxygen species (ROS) levels. Consistent with these findings, gene expression analyses
revealed dysregulation of metabolic pathways. Accordingly, blood ketone levels of Fibulin-4R/R mice were reduced and
liver fatty acids were decreased, while liver glycogen was increased, indicating dysregulated metabolism at the organismal
level. As predicted by gene expression analysis, the activity of PGC1a, a key regulator between mitochondrial function
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and organismal metabolism, was downregulated in Fibulin-4R/R VSMCs. Increased TGFb reduced PGC1a levels, indicating
involvement of TGFb signalling in PGC1a regulation. Activation of PGC1a restored the decreased oxygen consumption
in Fibulin-4R/R VSMCs and improved their reduced growth potential, emphasizing the importance of this key regulator.
....................................................................................................................................................................................................
Conclusion Our data indicate altered mitochondrial function and metabolic dysregulation, leading to increased ROS levels and
altered energy production, as a novel mechanism, which may contribute to thoracic aortic aneurysm formation.
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1. Introduction
Disorders of the heart and blood vessels, together known as cardiovas-
cular disease (CVD), are a leading cause of death. Most often patients
present with symptoms at a late and irreversible stage. A striking exam-
ple is aneurysmal disease, of which the incidence increases with age.
Aneurysms are large dilatations of the aorta that, when not detected in
time, will result in aortic rupture associated with high mortality. This dila-
tion of the aorta frequently occurs unnoticed up to a point where sur-
gery is the only optional treatment left. Although most risk factors, such
as lifestyle and age are known, the molecular mechanisms involved are
often not yet fully understood. Without this knowledge, proper diagno-
sis and intervention treatments are difficult to implement.
The most important factors known to be involved to date are extra-
cellular matrix (ECM) degeneration and alterations in the renin–angio-
tensin system (RAS) and transforming growth factor b (TGFb) signalling
pathways.1–8 In fact, intervention strategies based on these targets are
being explored.9 Although some mitigating effects on degeneration and
dilatation of the aorta have been observed, none of these treatments
rescue the disease or reverse symptoms.10–12 This must mean that still
many processes and molecules involved need to be identified to com-
plete the picture of how aneurysms are formed and progress.
To study the molecular mechanisms that underlie aneurysm forma-
tion, we developed a Fibulin-4 mouse model.13–15 Fibulin-4 is a secreted
glycoprotein, which is expressed in medial layers of blood vessels and is
a critical component for the structural integrity and elasticity of the aor-
tic wall.16–18 Fibulin-4 protein levels in the aorta are essential for vascular
maturation. The protein is located in microfibril bundles which tether
elastic fibres to smooth muscle cells via integrin-mediated binding to
regions of the cell membrane that are occupied by intracellular
membrane-associated anchoring sites for actin filaments.19 Insufficient
levels of Fibulin-4 compromise the structural integrity of the aortic wall,
which can lead to aneurysm formation. In agreement, patients with muta-
tions in Fibulin-4 suffer from cardiovascular complications including aor-
tic aneurysms, arterial tortuosity, and elastin abnormalities.20–22
Fibulin-4 is an essential gene and complete deletion of this gene in the
mouse leads to perinatal lethality.23 However, in our Fibulin-4R/R mouse
model, Fibulin-4 is 4-fold reduced13, resulting in severe aortic aneurysms
with associated aortic valve disease, thereby closely mimicking aneurysm
formation of genetically affected patients. Notably, genome-wide aorta
transcriptome and histological analyses of young Fibulin-4R/R animals
revealed TGFb signalling as one of the critical events in the pathogenesis
of the observed aneurysm formation.13
In this study, in order to identify additional underlying molecular
mechanisms that may contribute to aneurysm formation, we performed
proteomics, genomics, and functional experiments on aortas of adult
Fibulin-4R/R animals. Mostly, proteomics data reports on the absence or
presence of certain proteins, whereas gene expression profiling data are
subjected to pathway analysis. We hypothesized that by performing
pathway analysis on our proteomics data, and by comparing gene and
protein expression, this would hint us towards new important pathways
that additionally play a role in aneurysm formation. Our omics data point
to the fact that altered mitochondrial function and metabolism accom-
pany aneurysm formation in Fibulin-4R/R mice, which we substantiate
with functional experiments. These findings offer new mechanistic
insights into the complex disease of aneurysm formation.
2. Methods
2.1 Experimental animals
Fibulin-4þ/R animals were bred into in a C57BL6 background to obtain
Fibulin-4R/R and wild-type mouse (Fibulin-4þ/þ) experimental animals
(backcross 7). Fibulin-4SMKO animals, with deletion of Fibulin-4 in VSMCs
specifically, were kindly provided by Hiromi Yanigasawa24 and bred into
the same C57BL6 background. The numbers of animals used for each ex-
periment are described in the Results section and mentioned in figures
and/or figure legends. For each experiment with mutant animals, littermate
controls were used unless stated otherwise. Animals were housed at the
Animal Resource Centre (Erasmus University Medical Centre), which
operates in compliance with the ‘Animal Welfare Act’ of the Dutch gov-
ernment, using the ‘Guide for the Care and Use of Laboratory Animals’ as
its standard. As required by Dutch law, formal permission to generate and
use genetically modified animals was obtained from the responsible local
and national authorities. An independent Animal Ethics Committee con-
sulted by ErasmusMedical Center (StichtingDECConsult) approved these
studies (permit number 140-12-05), in accordance with national and inter-
national guidelines. For the described experiments animals were sacrificed
by CO2 inhalation, unless stated otherwise. This study conforms to the
guidelines from Directive 2010/63/EU of the European Parliament on the
protection of animals used for scientific purposes or theNIH guidelines.
2.2. Preparation of aorta protein extracts
and MS/MS protein identification
Fibulin-4R/R and Fibulin-4þ/þ littermate control mice (n=2 per group, fe-
male) were sacrificed at an age of 80–90 days, and thoracic aortas were
collected. Next, aorta protein extracts were made and protein concen-
tration was determined as described.25 Equal amounts of total protein
were loaded and size separated on a gradient (5–20%) SDS gel.
Subsequently, gels were stained with Coomassie Brilliant Blue. Lanes
were excised from the gel and 5mm slices were subjected to destaining,
in-gel reduction with dithiothreitol, alkylation with chloroacetamide and
digestion with trypsin (Promega, sequencing grade), essentially as de-
scribed.26 For Nanoflow LC-MS/MS details see Supplementary material
online. The analysis was performed in duplicate on independent samples
(n=2 per genotype). Proteins with a Mascot score of 60 and higher with
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a unique peptide count of at least 1, were taken into account for both
genotypes separately. To perform an Ingenuity Pathway Analysis (IPA),
lists of proteins identified in Fibulin-4R/R and Fibulin-4þ/þ aortas were
aligned and assessed for proteins only present in one or the other, or
both. Next, proteins only present in Fibulin-4R/R aortas were designated
‘up’. Likewise, proteins only present in Fibulin-4þ/þ aortas, thus absent in
Fibulin-4R/R were designated ‘down’. Also, for enrichment of the IPA
analysis, we took into account proteins present in both genotypes; pro-
teins with a unique peptide count either two-fold higher or two-fold
lower in Fibulin-4R/R compared to Fibulin-4þ/þ were designated ‘up’ and
‘down’, respectively. For proper IPA analysis, arbitrary signs ofþ2 and -2
were given to a protein designated up or down, respectively. A total of
374 proteins were fed into IPA (80 down, 294 up; also see
Supplementary material online, Tables S1 and S2).
2.3 GO-term analysis
To classify proteins according to gene ontology (GO) terms, we used
the AgBAse GOretriever for GO-term retrieval, which classifies pro-
teins on the basis of cellular components (http://agbase.msstate.edu/cgi-
bin/tools/goretriever_select.pl). For the 374 proteins that were identified
as different between Fibulin-4R/R and Fibulin-4þ/þ, 342 could be assigned
with a GO-term. These were separated into 12 categories: nucleus, cy-
toplasm, cytoskeleton, ECM, mitochondrion, proteasome, plasma mem-
brane, ribosomes, endoplasmatic reticulum and sarcoplasmic reticulum
(ER and SR), golgi and other (includes all other cellular components not
mentioned before), and unknown. For each category, percentages were
calculated by dividing proteins present in such category by all proteins
assigned with a GO-term.
2.4 Microarray experiments
Total thoracic aorta RNA of 3-month old Fibulin-4þ/þ (n= 3) and
Fibulin-4R/R (n= 2) was obtained using standard procedures (Qiagen).
Labelling, hybridization, and scanning of Affymetrix Mouse Exon 1.0 ST
microarrays (Affymetrix, Mountain View, CA, USA) were performed
according to standard Affymetrix protocol (http://www.affymetrix.com/
support/technical/byproduct.affx? product=moexon-st). Raw intensity
values of all samples were normalized by robust multichip analysis nor-
malization (background correction and quantile normalization) using
Partek version 6.5 (Partek Inc., St. Louis, MO, USA). Principal component
analysis showed good separation of the two sample sets. Differential
expressed genes were identified using ANOVA (Partek). Cut-off values
for significantly expressed genes: P-value <_0.03 and -1.5 <_ fold change >_
þ1.5. Functional analysis was performed using IPA (Ingenuity, Redwood
City, CA, USA). Upstream regulators were selected by P-value <0.01,
Bias-corrected z-score >2 and <-2. For the comparison of adult and new-
born Fibulin-4R/R gene expression data, we used the Fibulin-4R/R newborn
data previously published by Hanada et al.13 This comparison resulted in
106 overlapping, significantly regulated genes (FC> 1.2; P<0.05), of
which 99 were regulated in the same direction. These 106 overlapping
genes were used for pathway analysis in IPA. For upstream regulator
analysis the same selection criteria were used as mentioned above.
2.5 RNA isolation and real-time PCR
Liver and aortic tissue from Fibulin-4þ/þ and Fibulin-4R/R mice, snap fro-
zen and stored at -80C, was used for this experiment. RNA from aortic
tissue was isolated with the miRNeasy mini kit (Qiagen) and liver RNA
with RNeasy mini kit (Qiagen). cDNA was made with iScript cDNA syn-
thesis kit (Biorad) according to manufacturing protocol. Q-PCRwas per-
formed with 200nM forward and reverse primers and iQTM SYBR
VR
Green Supermix (biorad) on the CFX96 system (Biorad); denaturation
at 95C for 3min, 40 cycles denaturation at 95C for 15 s, annealing/ex-
tension at 55C for 30 s. B2M was used as a housekeeping gene. Relative
gene expression levels were determined with the comparative Ct
method. See Table 1 for primers used.
2.6 Cell culture
Mice (aged 100 days) were euthanized by an overdose of CO2 and
autopsied according to standard protocols. Primary vascular smooth
muscle cells (VSMCs) were isolated according to the method of
Proudfoot and Shanahan,27 from the thoracic aorta of Fibulin-4þ/þ,
Fibulin-4R/R, and Fibulin-4SMKOmice and cultured on gelatinized dishes in
Dulbecco’s Modified Eagle’s Medium (DMEM) (Lonza BioWhittaker)
supplemented with 1% penicillin–streptomycin (PS) and 10% foetal calf
serum (FCS). Tgfbr-1M318R/þ and control VSMCs were kindly provided
by Hal Dietz and Elena MacFarlane.28 VSMCs were used until passage 10
for experiments described unless stated otherwise. Human patient fibro-
blasts with Fibrillin-1 (FBN1 c.4817-1G>A: FBN1 ex 39), TGFb receptor
2 (TGFBR2 c.1573delA: TGFBR2 ex 07) and Smad3 (SMAD3 c.859C>T,
p.R287W: SMAD3 ex 9) mutations were kindly provide by D.F. Majoor-
Krakauer, I.B.M.H. van der Laar, and J.M.A. Verhagen. All patients pro-
vided written informed consent for participation in the study, and this
study conforms to the principles outlined in the Declaration of Helsinki.
For the proliferation assay, cells were used at passages 7 and 8.
Fibulin-4þ/þ and Fibulin-4R/R VSMCs were seeded in triplicate in 6 cm
dishes (5000 cells/dish) and allowed to attach. Cells were fixed overnight
at 4C with 10% trichloroacetic acid (TCA, Sigma-Aldrich, T9159) at
Days 1, 2, 3, 6, and 7 after seeding. A sulforhodamine beta (SRB) assay
for proliferation was performed after collection of all time points. The
fixed and dried dishes were incubated for 20min with 0.5% SRB solution
(Sigma-Aldrich, S9012) in 1% acetic acid and excess SRB was removed
by washing with 1% acetic acid. After drying, bound SRB was dissolved in
10mM TRIS (Sigma-Aldrich, T6066). Absorbance was measured at
560 nm, and the percentage of growth was calculated at each day relative
to the number of cells at Day 1.
..............................................................................................................................................................................................................................
Table 1 Primer sequences used for real-time PCR
Fw seq Rev seq Size
PPARa AACATCGAGTGTCGAATATGTGG CCGAATAGTTCGCCGAAAGAA 99
PPARc CACAATGCCATCAGGTTTGG GCTGGTCGATATCACTGGAGATC 82
PGC1a CTGCGGGATGATGGAGACAG TCGTTCGACCTGCGTAAAGT 101
PGC1b GGGAAAAGGCCATCGGTGAA CAGCACCTGGCACTCTACAA 122
B2M CTCACACTGAATTCACCCCCA GTCTCGATCCCAGTAGACGGT 98
Reduced mitochondrial respiration in Fibulin-4 mice 3
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2.7 Mitochondrial respiration
Oxygen consumption rates (OCR) and extracellular acidification rate
(ECAR) were measured using an XF-24 Extracellular Flux Analyzer
(Seahorse Bioscience). Respiration was measured in XF assay media
(non-buffered DMEM containing 2mM L-glutamine, 100mM sodium py-
ruvate, and 5mM glucose), in basal conditions and in response to 1lM
oligomycin (ATP synthase inhibitor), 1lM fluorocarbonyl cyanide phe-
nylhydrazone (FCCP, uncoupler), 1lM rotenone (Complex I inhibitor),
1lM antimycin A (Complex III inhibitor). VSMCs and mouse embryonic
fibroblasts (MEFs) were seeded at a density of 30 000 cells/well and ana-
lysed after 24 h. Optimal cell densities were determined experimentally
to ensure a proportional response to FCCP with cell number. ECAR
was measured during the entire experiment. For these experiments
three independent cell lines were used per genotype, for which 6–8wells
were measured per time point.
2.8 Oxygraph and mitochondrial complex
activity measurements
Tissue homogenates were prepared from frozen muscle in 0.25M su-
crose, 10mM N-[2-hydroxyethyl] piperazine-N0-[2 ethylsulfonic acid]
(HEPES) and 1mM ethylene diamine tetra-acetic Acid (EDTA), pH 7.4.
Mitochondrial respiratory activity, measured as OCR (flux in pmol O2/s/
mg mitochondrial protein) was assessed at 37C by high-resolution respi-
rometry (Oxygraph-2k, Oroboros Instruments). Complexes I- and II-
dependent respiration were measured in state 2 (respectively, in the
presence of 2mmol/L malate and 10mmol/L glutamate, and in the pres-
ence of 10mmol/L succinate) and state 3 (in the presence of substrates
and 0.25mmol/L ADP). To prevent retrograde flux of electrons via
Complex I, Complex II-dependent respiration was measured in the pres-
ence of 0.5lmol/L of the Complex I inhibitor rotenone. Respiratory ade-
nylate control index (RCI) was calculated by dividing oxygen flux in state
3 by the flux in state 2. For complex activity measurements, see
Supplementary material online.
2.9 Registration of reactive oxygen species
with molecular imaging
Mice were anaesthetized (isoflurane 2%, O2 2 L/min) and visualized using
the IVIS spectrum imaging system (Perkin Elmer). L-012 (8-amino-4-
chloro-7-phenylpyridol[3,4-d]pyridazine-1, 4(2H, 3H)dione, a chemi-
transluminescent probe and derivative of luminol, was purchased from
Wako Chemical (Neuss, Germany) and dissolved in H2O. A concentra-
tion of 75mg/kg in a volume of 100lL was administered intravenously.
Images were taken with the IVIS Spectrum imaging system (Perkin
Elmer). For molecular imaging, mice were sacrificed after an hour by an
overdose of anaesthesia, and the chest was opened according to stan-
dard necropsy protocols. Data acquisition and analysis were performed
using IVIS imaging software Living Image (Caliper). The photon flux was
quantified within a region of interest encompassing the thoracic chest re-
gion of each mouse. The signal was normalized against an illumination
profile for the selected field of view. Also see reference. 29
2.10 DHE staining
Cryosections 10lm thick were stored at -80C. After thawing the sec-
tions, they were stained by 5lM dihydroethidium (DHE) and 0.5lg/mL
Hoechst 33258 in phosphate buffered saline (PBS) for 30min at 37C in
a humidified atmosphere. The fluorescence of the superoxide specific re-
action product of DHE oxidation was measured using a fluorescence
inverted microscope (Olympus IX50) equipped with a 460–490 nm
band pass excitation filter and 515 nm emission IF-barrier filter, digitized
with an F-view camera (Soft Imaging System, Mu¨nster, Germany), and
analysed offline (AnalySIS 3.1; Soft Imaging System). To determine the in-
tegrated density ratio, we first determined the sum of the fluorescence
values of the pixels in the ethidium (red) and 2-OH-ethidium (green) se-
lection separately. Subsequently, the integrated intensity ratio was deter-
mined by dividing the 2-OH-ethidium (green) values over the ethidium
(red) values for the individual samples.
2.11 PGC1a luciferase assay
Fibulin-4þ/þ and Fibulin-4R/R VSMCs were transiently transfected using
lipofectamine 2000 (Invitrogen). Cells were dually transfected with
PGC1a 2 kb firefly luciferase plasmid (Addgene plasmid 888730) and
SV40-renilla luciferase plasmid (10:1). After 24 h, cells were washed with
PBS, replenished with medium containing low serum (0.2% FCS) and
cells were either treated overnight with TGFb1 (5ng/mL, Biovision) to
stimulate TGFb signalling, SB431542 hydrate (10mM, Sigma), inhibitor of
the TGFb receptor, Forskolin (10mM, Sigma) for PGC1a activation, or
DMSO as a negative control. After 24 h, cells were lysed and firefly/
renilla luciferase ratio was determined with the dual-luciferase assay sys-
tem (Promega) using Glomax- multiþ detection (Promega) for each cell
line. Relative luciferase levels were calculated by using the untreated
Fibulin-4þ/þ VSMCs (control) as reference value.
2.12 Statistical analysis
All experiments described were performed blinded by using cell line and
mouse numbers without genotypes. Normal distribution of the data was
assessed using the Shapiro Wilk test. The unpaired two-tailed Student’s t-
test was performed to analyse the specific sample groups for significant dif-
ferences. All results are expressed as mean± SEM. However, for data with
non-normal distribution, log-transformation of the data, followed by the
Student’s t-test, was performed. A P-value <0.05 was considered to indicate
a significant difference between groups. In the figures, P<0.05 or P<0.01 is
shown with * and P<0.001 with **. All analyses were performed using IBM
SPSS Statistics version 21.0 (SPSS Inc., Chicago, IL, USA) or Graphpad.
3. Results
3.1 Proteomics analysis identifies
increased mitochondrial protein levels
in Fibulin-4R/R aortas
For the proteomics analysis, protein extracts isolated from 3-month old
thoracic aortas of Fibulin-4R/R and Fibulin-4þ/þ animals were used.
Reduction of Fibulin-4 protein was confirmed by western blot
(Supplementarymaterial online, Figure S1A, left panel). Proteome expres-
sion profiles were analysed using a 1D gradient gel of total aorta protein
extract. Next, proteins separated on the gel were trypsin digested and
identified by an MS/MS method coupled to Mascot database searches
(Supplementary material online, Table S1). A duplicate analysis of the
samples identified more than 75% of the proteins in the first analysis.
Analysis of an independent set of aorta extracts identified more than
65% of the previously identified proteins.
To determine differences in the proteome of Fibulin-4R/R and Fibulin-
4þ/þ aortas, we used a Mascot score cut-off of 60. This resulted in a total
of 695 proteins, of which 494 identified proteins for Fibulin-4þ/þ and
655 identified proteins for Fibulin-4R/R aorta. IPA was performed on a se-
lection of proteins that were either present or absent, as well as proteins
4 I. van der Pluijm et al.
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with a two-fold higher or lower peptide count, in Fibulin-4R/R vs. Fibulin-
4þ/þ aorta, designated over- and under-represented, respectively. This
resulted in 80 proteins that were over-represented in Fibulin-4þ/þ com-
pared to Fibulin-4R/R aorta and 294 proteins that were over-represented
in Fibulin-4R/R compared to Fibulin-4þ/þ, leaving 321 proteins designated
as ‘not changed’ between Fibulin-4þ/þ and Fibulin-4R/R (Supplementary
material online, Table S2 and Figure 1A).
To verify this approach, we subsequently checked whether we could
find proteins known to be associated with aneurysm formation based on
three important associated factors: the ECM, TGFb, and RAS signalling.
We used the AgBAse GOretriever for GO-term retrieval, which classifies
proteins on the basis of cellular components (http://agbase.msstate.edu/cgi-
bin/tools/goretriever_select.pl). Of the 374 proteins in total that were dif-
ferentially expressed between Fibulin-4R/R and wild-type mice, 342 GO-
terms could be assigned. Here, we observed that 14% of these proteins fell
into the category ‘ECM’ (Figure 1B). Moreover, compared to wild-type, in
the Fibulin-4R/R aorta we observed over-representation of the ECM pro-
teins elastin, fibrillin, fibronectin, laminin, and different collagen subtypes.
We performed confocal 3D imaging on aortic walls of Fibulin-4þ/þ and
Fibulin-4R/R mice, showing expanded and disorganized elastin structure in
the latter (Supplementary material online, Figure S1B). In addition, western
blot analysis showed increased amounts of elastin protein in Fibulin-4R/R
compared to Fibulin-4þ/þ aortic extracts (Supplementary material online,
Figure S1C). Both results confirm the over-representation of the ECM pro-
teins that we observed in proteomics data. Next to this overabundance of
ECM proteins, 17% of the proteins fell into the category ‘cytoskeleton’.
Cytoskeleton proteins are closely connected to the ECM via integrins.
Unexpectedly, we also observed that 17% of all proteins with significantly
changed expression fell into the category ‘mitochondria’ (Figure 1B).
Next, the 374 deregulated proteins were loaded into IPA for further
analysis. Of these 374 protein IDs, 369 were mapped by IPA. We per-
formed both a pathway and an upstream regulator analysis to get an idea
of the changes in processes involved. TGFb1 itself turned out to be upre-
gulated and was also predicted to be activated (based on 69 deregulated
target molecules) as part of the upstream regulator analysis (Figure 1C).
Thus, the proteomics data points to involvement of TGFb signalling in
Fibulin-4 associated aneurysms as previously reported.13,22,31 Both ACE
as well as Rac1, which are part of the RAS pathway, were upregulated in
the protein dataset of Fibulin-4R/R compared to Fibulin-4þ/þ. Moreover,
angiotensinogen, a key molecule in the RAS pathway, was predicted to
be upregulated (Figure 1C). Indeed, previous analysis of mouse aortas
showed that angiotensinogen is increased in Fibulin-4R/R animals com-
pared to Fibulin-4þ/þ.5,7 In conclusion, our proteome analysis reveals de-
regulation of TGFb signalling and RAS, processes already known to be
changed in Fibulin-4R/R aneurysms, validating our approach.
Canonical pathway analysis (IPA) pointed towards changes in cytoskel-
eton and integrin signalling (Figure 1D), as did the GO-analysis, which fits
with Fibulin-4’s functions within the ECM. Interestingly, mitochondrial dys-
function was also a significantly changed canonical pathway, which fits with
the findings of the GO analysis showing a protein over-representation in
the category ‘mitochondria’. Taken together, next to factors known to be
changed in aneurysm formation, our proteomics data analysis suggests
changes in mitochondrial function in the aortas of Fibulin-4R/R animals.
3.2 Decreased OCR in mutant Fibulin-4
and TGFb-1 receptor VSMCs
To investigate mitochondrial function, we analysed mitochondrial respi-
ration using a Seahorse XF-24 Extracellular Flux Analyzer, which allows
simultaneousmeasurement of theOCR and the ECAR.While OCR indi-
cates respiration, ECAR reflects lactate production and thus glycolytic
flux. OCR and ECAR thus provide a comprehensive estimate of the bio-
energetics properties of the studied specimen. We observed a signifi-
cantly decreased basal respiration (without addition of any inhibitor) in
Fibulin-4R/R VSMCs compared to Fibulin-4þ/þ controls (Figure 2A,B,
Phase I, P<0.01). While no differences were observed in respiration af-
ter injection of the ATP synthase inhibitor oligomycin, the addition of
FCCP, an oxidative phosphorylation (OXPHOS) uncoupler eliciting
maximal respiration, indicated a significantly lower maximal OCR in
Fibulin-4R/R VSMCs (Figure 2A,B, Phase III, P<0.01). Complete repression
of respiration by the combined addition of Complex I inhibitor rotenone
and Complex III inhibitor antimycin A, led to the same OCR in Fibulin-
4R/R and Fibulin-4þ/þ VSMCs, indicating that besides mitochondrial respi-
ration, oxygen consumption differences due to other cellular processes
are negligible (Figure 2A). Experiments were repeated three times with
two independent cell lines per genotype which gave similar consistent
results (Figure 2B). Interestingly, ECAR was consistently higher in Fibulin-
4R/R compared to Fibulin-4þ/þ VSMCs (Figure 2C,D, P<0.01), which
might be indicative of metabolic rearrangements to compensate for mi-
tochondrial defects in Fibulin-4R/R cells. Interestingly, lower basal and
maximum OCR were also observed in MEFs of Fibulin-4R/R mice com-
pared to Fibulin-4þ/þ control mice, highlighting that decreased oxygen
consumption is a general phenomenon in the Fibulin-4 R/R mouse model
(Supplementary material online, Figure S2, P<0.01).
We next wanted to verify that the observed defect in mitochondrial
function is due to reduced Fibulin-4 in Fibulin-4R/R cells, rather than po-
tential secondary effects associated with the engineered allele. To this
end, we isolated Fibulin-4SMKO VSMCs from the Fibulin-4SMKO mouse, in
which Fibulin-4 is knocked out in the smooth muscle cells specifically.
Absence of Fibulin-4 in Fibulin-4SMKO aortic extracts was verified by
western blot (Supplementary material online, Figure S1A right panel). We
then performed the same Seahorse experiments as described above for
the Fibulin-4R/R VSMCs. Interestingly, also these Fibulin-4SMKO VSMCs
showed a significant reduction in both basal and maximal OCR com-
pared to Fibulin-4þ/þ VSMCs (Figure 2E, P<0.01), demonstrating that
Fibulin-4 deletion results in the observed defects in mitochondrial respi-
ration similar to those in the Fibulin-4R/R VSMCs. We did not observe
significant changes in the ECAR compared to Fibulin-4þ/þ VSMCs (data
not shown).
We were interested whether the same decreased OCR was present
in VSMCs from other aneurysmal syndromes. This prompted us to first
measure mitochondrial respiration in VSMCs obtained from the Tgfbr-
1M318R/þ mouse, a model for Loeys-Dietz syndrome (LDS).28 Similar to
Fibulin-4R/R and Fibulin-4SMKO VSMCs, Tgfbr-1M318R/þ VSMCs showed a
reduced basal and maximal OCR compared to Tgfbr-1þ/þ VSMCs
(Figure 2F). We did not observe an obvious decrease in ECAR as seen
for Fibulin-4R/R VSMCs (data not shown). To examine whether oxygen
consumption is also affected in cells of Marfan and Loeys-Dietz patients,
we set out to measure mitochondrial respiration in patient cell lines.
Although we did not have access to human VSMCs, we were able to ob-
tain human fibroblasts from aneurysmal patients with Fibrillin-1 (FBN1
c.4817-1G>A: FBN1 ex 39), TGFb receptor 2 (TGFBR2 c.1573delA:
TGFBR2 ex 07), and Smad3 (SMAD3 c.859C>T, p.R287W: SMAD3 ex
9) mutations, as well as three control cell lines.We next used the human
patient fibroblasts to perform seahorse experiments. Interestingly, all
three patient cell lines showed a significantly reduced basal and maxi-
mum OCR compared to the control cell lines (Figure 2G,H). From these
data, we conclude that the altered mitochondrial oxygen consumption
Reduced mitochondrial respiration in Fibulin-4 mice 5
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Figure 1 Proteomics analysis of Fibulin-4R/R and Fibulin-4þ/þ thoracic aortas identifies mitochondrial function as potentially affected. (A) Venn diagram
comparison of proteins identified in Fibulin-4þ/þ (left circle) and Fibulin-4R/R (right circle) aortas; on the left side proteins over-represented in Fibulin-4þ/þ
aortas (light blue), on the right side proteins over-represented in Fibulin-4R/R aortas (dark blue). Overlap between the two circles represents proteins
that exhibit no chance between the two groups. (B) Pie graph of GO-term distribution of proteins differentially regulated in Fibulin-4R/R compared to
Fibulin-4þ/þ aorta. Cytoskeleton (17%), extracellular matrix (ECM, 14%), and mitochondria (17%) together comprise 48% of differentially regulated pro-
teins. (C) Table depicting predicted activation or inhibition of Upstream Regulators (-2> bias-corrected z-score> 2, P-value <0.01), derived from an IPA
analysis based on differentially regulated proteins in Fibulin-4R/R compared to Fibulin-4þ/þ aortas. Notably, TGFb1 and Angiotensinogen (AGT) are
6 I. van der Pluijm et al.
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in aneurysms is not restricted to Fibulin-4 mutations per se but is present
in VSMCs and fibroblasts of multiple thoracic aneurysmal aorta
syndromes.
3.3 Complexes I, III, IV, and V levels and
activity in Fibulin-4R/RVSMCs and tissues
To investigate whether mitochondrial localization was affected by
Fibulin-4 mutation, we first stained two independent Fibulin-4R/R and
Fibulin-4þ/þ VSMC cell lines used in the Seahorse experiments with
Mitotracker CMX Ros and SiR-Actin. We observed no differences in mi-
tochondrial localization or obvious differences in cytoskeletal composi-
tion between Fibulin-4 mutant or control cell lines (Figure 3A). We next
performed fluorescence-activated cell sorting (FACS) experiments using
Fibulin-4R/R and Fibulin-4þ/þ VSMCs with the Mitotracker CMX Ros
probe to determine the number of mitochondria per cell. From this
analysis we observed no differences in mitochondrial signals, indicating
no change in number of mitochondria per cell (Figure 3B). The observed
differences in mitochondrial function in Fibulin-4R/R and Fibulin-4þ/þ cells
prompted us to examine mitochondrial structure in VSMCs of the aorta
by electron microscopy (EM). The mitochondrial ultrastructure in
Fibulin-4þ/þ and Fibulin-4R/R cells appeared similar, although the Fibulin-
4R/Rmitochondria seemed somewhat reduced in size (Figure 3C).
The clear differences in mitochondrial respiration, without affecting
the number of mitochondria per cell, could imply an altered mitochon-
drial mass (i.e. total mitochondrial volume in the cell) in Fibulin-4R/R
VSMCs. In turn, this could indicate less mitochondrial complexes per
cell, leading to decreases in OCR. However, the proteomics data
showed a higher expression of mitochondrial complex proteins involved
in OXPHOS. To investigate expression of mitochondrial complex pro-
teins, we performed western blot analysis using thoracic aorta tissue
with an antibody cocktail directed against five specific OXPHOS I-V
complex subunits that are labile when its complex is not assembled.
Interestingly, when compared to Fibulin-4þ/þ, the protein level of
Complexes I through IV was significantly (P<0.05) increased in Fibulin-
4R/R aortas, whereas Complex V showed no significant change (Figure
3D,E). This is in agreement with the results from the proteomics analysis
which showed that several individual mitochondrial complex proteins
are upregulated. This could indicate a partial compensatory reaction of
the respiratory electron transport chain (ETC) to counteract the de-
crease in mitochondrial mass. We also performed this western blot on
Fibulin-4SMKO aortic extracts and littermate controls, to see if deleting
Fibulin-4 in VSMCs alone could result in overexpression of these com-
plexes. Indeed, we observed overexpression of Complexes I–IV in
Fibulin-4SMKO (Supplementary material online, Figure S1D), however this
was not a significant difference, indicating that other cells in the aorta of
Fibulin-4R/R animals may also contribute to this effect.
To see if decreased OCR is not limited to the aorta, we measured re-
spiratory capacity in aorta, heart, muscle, and liver of Fibulin-4þ/þ and
Fibulin-4R/R animals. Unfortunately, we were unable to determine OCR
in aortic extracts, probably due to rigidity of the tissue because of ECM
content. Nevertheless, heart and skeletal muscle, containing large
amounts of muscle cells and highly dependent on mitochondrial activity,
both showed a significantly lower OCR (Figure 3F). The liver did not
show a lower, but somewhat higher (non-significant) OCR (Figure 3F),
which we would expect if the observed OCR decrease is muscle cell
specific. To determine whether the decreased oxygen consumption was
due to reduced mitochondrial complex activity, we measured individual
Complexes I, III, IV, and V activities (II is not subject to change), but ob-
served no significant change (Figure 3G). These data fit with the observa-
tion that more Complexes I–IV proteins are present in the aorta (Figure
3D,E). Taken together, we can conclude that the reduced oxygen con-
sumption is not due to lower complex activity.
3.4 Molecular imaging reveals increased
ROS in the aorta of Fibulin-4R/R animals
The observed imbalance between mitochondrial mass and the expres-
sion and activity of mitochondrial enzyme complexes may lead to an in-
crease in generation of reactive oxygen species (ROS). In this context,
we did observe a somewhat lower ADP ratio in Fibulin-4R/Rmuscular tis-
sues (data not shown), which would imply less efficient ATP production
that could lead to more radical formation. To investigate if indeed more
radicals are present, we performed molecular imaging using the L-012
probe. This probe emits a luminescent signal upon interaction with reac-
tive oxygen and nitrogen species that is quantified using an IVIS spectrum
imaging system. We injected Fibulin-4R/R and Fibulin-4þ/þ animals with
the L-012 probe and recorded the luminescent signal from the opened
chest of mice after 1 h to determine the signal localization. Experiments
were performed three times with each Fibulin-4R/R animal matched to a
Fibulin-4þ/þ littermate control. We observed a significant increase in av-
erage L-012-derived luminescence in Fibulin-4R/R aortas compared to
Fibulin-4þ/þ (Figure 4A,B, P<0.05). Consistently, staining of Fibulin-4R/R
aortic sections with the superoxide indicator DHE showed increased 2-
OH-ethidium fluorescence compared to Fibulin-4þ/þ, indicative of in-
creased superoxide levels (Figure 4C, P<0.05). Together, these data
show that ROS levels are elevated in Fibulin-4R/R aortas.
3.5 Systemic metabolic analyses indicate a
metabolic switch towards fatty acid
oxidation in Fibulin-4R/R animals
Previous gene expression studies performed on young Fibulin-4R/R ani-
mals gave insight into the mechanism of aneurysm formation, amongst
which were cytoskeleton re-organization and perturbed TGFb signal-
ling.13 As we observed many changes at the protein level pointing to-
wards mitochondrial involvement, we wondered whether this would
also be reflected at the transcriptional level. Additionally we were inter-
ested whether gene expression profiles could point to potential mecha-
nisms and targets involved. Therefore, we performed gene expression
analyses on 3-month old Fibulin-4þ/þ and Fibulin-4R/R thoracic aortas by
using GeneChip mouse exon 1.0 ST arrays (Affymetrix). The obtained
gene expression differences (P-value of 0.03; fold change 1.2) were
uploaded and analysed in IPA. Canonical pathway analysis pointed to-
wards numerous pathway changes related to metabolism (see Figure 5A
Figure 1 Continued
predicted to be upregulated, which is known from literature, thus validating this prediction approach. (D) Graph depicting the top 10 significantly
changed (P<0.01) canonical pathways, derived from an IPA analysis based on the differentially regulated proteins in Fibulin-4R/R compared to
Fibulin-4þ/þ aortas. Mitochondrial dysfunction is the 6th most significantly changed canonical pathway.
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Figure 2 Reduced OCR and increased ECAR in Fibulin-4 deficient VSMCs. (A) Graph depicting the oxygen consumption rate (OCR) in Fibulin-4R/R
VSMCs (dark blue squares) and Fibulin-4þ/þ VSMCs (light blue squares) at basal level (I) and after addition of oligomycin, a Complex V inhibitor (II), FCCP,
an OXPHOS uncoupler, for maximum OCR measurement (III), and a combination of rotenone (Complex I inhibitor) and antimycin A (Complex III inhibi-
tor), showing potential OCR differences not due to mitochondria (IV). (B) Both at basal level (I) and at maximum oxygen consumption level (III) Fibulin-4R/R
VSMCs show a significantly lower OCR compared to Fibulin-4þ/þ (P<0.01, Student’s t-test), indicating altered mitochondrial function. The scatter plot
shows absolute OCR levels from three experiments that were performed in two independent cell lines per genotype. (C) Graph depicting the extracellular
acidification rate (ECAR) in Fibulin-4R/R and Fibulin-4þ/þ VSMCs. (D) ECAR is significantly elevated in Fibulin-4R/R compared to Fibulin-4þ/þ VSMCs
(P<0.01, Student’s t-test), quantified at basal (I) and maximumOCR (III). The scatter plot shows ECAR levels from three experiments that were performed
in two independent cell lines per genotype. (E) Scatter plots showing basal (I) and maximum (III) OCR levels in Fibulin-4SMKO VSMCs (dark blue circles),
which are knock-out for Fibulin-4 in VSMCs specifically, and Fibulin-4þ/þ VSMCs (light blue circles), for three experiments that were performed in two
8 I. van der Pluijm et al.
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for the top 10); out of the 30 canonical pathways predicted to be signifi-
cantly changed (P<0.01), 73% are directly involved in metabolic pro-
cesses (data not shown). Moreover, when we examine the first 10
networks significantly changed based on our gene dataset, at the first po-
sition we find ‘Energy Production/Lipid Metabolism/Small Molecule
Biochemistry’ (Supplementary material online, Figure S3).
To investigate if metabolic changes observed in the thoracic aorta are
also reflected systemically in the mouse, we first analysed body weights
of the mice. Indeed, Fibulin-4R/R animals (n=38) had a significantly lower
body weight than Fibulin-4þ/þ animals (Figure 5B, P<0.05). Next, we ex-
amined three important metabolic parameters: glucose, lactate, and
ketones in blood of non-fasted Fibulin-4þ/þ and Fibulin-4R/R animals.
These parameters together shed light on the main metabolic processes
used to generate ATP. Both blood glucose levels as well as blood lactate
did not show significant differences between the two genotypes (Figure
5C,D). However, blood ketone levels were significantly lower in Fibulin-
4R/R compared to Fibulin-4þ/þ animals (Figure 5E, P<0.01). Interestingly,
in our gene expression analysis, we found that the key enzyme responsi-
ble for breakdown of ketones, is significantly upregulated in the aorta (3-
oxoacid CoA transferase, OXCT1, 1.3-fold, P=0.03, Supplementary
material online, Figure S6A). In addition, IPA analysis revealed many genes
involved in the citric acid cycle [tricarboxylic acid cycle (TCA)] pathway
significantly downregulated in Fibulin-4R/R compared to Fibulin-4þ/þ aor-
tas (Supplementary material online, Figure S4A).
The liver is a central organ involved in metabolism and adjusts meta-
bolic processes to energy demands of the different tissues within an or-
ganism. Since ketones are products of fatty acid oxidation in the liver, we
next performed oil-red-o staining on livers isolated from Fibulin-4þ/þ
and Fibulin-4R/R animals (n=5 per group) that were normally fed. These
animals did not show signs of malnutrition, or malabsorption of food in
the intestine, and the liver showed no overt abnormalities on H&E-
stained sections (data not shown). Yet, livers of Fibulin-4R/R animals
clearly showed reduced oil-red-o staining in all five animals examined as
compared to their respective Fibulin-4þ/þ littermates (Figure 5F,
P<0.01). In contrast, periodic acid-Schiff (PAS) staining for glycogen
showed the exact opposite; all five Fibulin-4R/R animals showed increased
glycogen accumulation compared to their respective Fibulin-4þ/þ
littermates (Figure 5G, P<0.01). We found no direct evidence for mal-
functioning mitochondria of the liver regarding the process of OXPHOS,
since these livers showed normal OCR, and immunoblots of liver
lysates from Fibulin-4R/R and Fibulin-4þ/þ animals did not show differen-
ces in the amount of the various OXPHOS complexes (Supplementary
material online, Figure S4B). This could be due to absence or low ex-
pression of Fibulin-4 in the liver. Thus, based on the reduction of fatty
acids in the liver together with reduction of ketones in the blood, it is
likely that metabolism in the liver of Fibulin-4R/R mice has shifted to fatty
acid b-oxidation and the production of ketone bodies, to meet the
altered demand in energy carrier type (ketone bodies vs. glucose) by
the aneurysmal aorta.
We next compared the gene expression data of newborn Fibulin-4R/R
aortas, previously published by Hanada et al.,13with the gene expression
data of adult Fibulin-4R/R aortas. This comparison resulted in 106 over-
lapping, significantly regulated genes (FC>1.2; P<0.05) used for IPA
analysis, of which 99 were regulated in the same direction. Canonical
pathway analysis showed processes involved in fat and glucose metabo-
lism significantly regulated, such as atherosclerosis signalling, PPARa/
RXRa signalling and glycolysis, in common between newborn and adult
aortas (Supplementary material online, Figure S5A), which may hint to
processes that are important from an early time point on for aneurysm
formation in these animals. Moreover, upstream regulator analysis pre-
dicted, amongst others, TGFB1, miR-29b, and PPARG to be significantly
differentially regulated (Supplementary material online, Figure S5B).
Interestingly, TGFB1 and miR-29b have previously been published to be
altered in Fibulin-4R/R aortas,13,31,32 and are here also found to be impor-
tant key regulators. PPARGwas not previously identified but plays an im-
portant role in fat metabolism. As we observed changes in fat and
glycogen deposition in adult Fibulin-4R/R livers compared to Fibulin-4þ/þ
livers, we performed the same staining on newborn livers. However, we
did not observe obvious changes in fat or glycogen deposition between
Fibulin-4R/R and Fibulin-4þ/þ newborn livers (Supplementary material
online, Figure S5C, n=5 per genotype). These data together could indi-
cate that the aneurysmal induced changes in metabolic processes may
precede the metabolic changes in the liver.
3.6 Reduced PGC1a expression and activity in
aortas and VSMCs of Fibulin-4R/R animals
Since we discovered changes in mitochondrial function in thoracic aortas
of Fibulin-4R/R animals, it would be interesting to know which process or
subset of factors is responsible. To investigate this, we looked at up-
stream regulators that are predicted to be significantly changed based on
the gene expression data in the thoracic aorta of Fibulin-4R/R animals.
Interestingly, PGC1a and PGC1b (peroxisome proliferator-activated re-
ceptor gamma, coactivator 1 a and b) as well as PPARa, PPARd and
PPARc (peroxisome proliferator-activated receptor a, d, and c) were
predicted to be significantly downregulated (Table 2). In addition, we no-
ticed that they were also all significantly downregulated at the gene ex-
pression level, except for PPARd, which showed no significant change
(Table 2). Next, we performed real-time PCR analysis to check the
mRNA expression levels of PGC1a, PGC1b, PPARa, and PPARc in tho-
racic aorta extracts of Fibulin-4R/R and Fibulin-4þ/þ animals. We found
that mRNA levels of PGC1a and PGC1b were both significantly down-
regulated in Fibulin-4R/R compared to Fibulin-4þ/þ aortas (Figure 6A,
Figure 2 Continued
independent cell lines per genotype. Fibulin-4SMKO VSMCs show a significantly lower OCR compared to Fibulin-4þ/þ (P<0.01, Student’s t-test). (F)
Scatter plots showing basal (I) and maximum (III) OCR levels in Tgfbr-1M318R/þ (dark blue triangles) and Tgfbr-1þ/þ VSMCs (light blue triangles),
of three experiments that were performed in two independent cell lines per genotype. Both at basal (I) and at maximum OCR level (III)
Tgfbr-1M318R/þ VSMCs show a significantly lower OCR compared to Tgfbr-1þ/þ (P<0.01, Student’s t-test). (G) Graph depicting the oxygen con-
sumption rate (OCR) in three different human fibroblast cell lines derived from aneurysmal patients with a Fibrillin-1 (FBN1, dark blue squares),
TGFb receptor 2 (TGFBR2, blue diamonds), and SMAD3 (light blue circles) mutation, as well as the mean of three control cell lines (light blue
squares). (H) Scatter plots showing basal (I) and maximum (III) OCR levels, which are significantly lower for the humanmutant fibroblasts compared
to control (P<0.01, Student’s t-test). OCR observations were made in two independent experiments, in case of the controls for three independent
cell lines. All results are expressed as mean± SEM.
Reduced mitochondrial respiration in Fibulin-4 mice 9
Downloaded from https://academic.oup.com/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvy150/5042174
by University of Sheffield user
on 09 August 2018
AC
D E
F G
B
Figure 3 Mitochondrial size and complexes are affected in the thoracic aorta of Fibulin-4R/R animals. (A) Mitotracker and SiR-Actin staining of Fibulin-4R/R and
Fibulin-4þ/þ VSMCs showing a very similar distribution and pattern. The white line indicates a length of 20mm. (B) Scatter plot depicting mitotracker (CMXRos)
signal per cell, a measure for mitochondrial number per cell. No significant difference was observed (Student’s t-test). Mitotracker experiments were performed
for n=3 (Fibulin-4R/R) and n= 5 (Fibulin-4þ/þ) cell lines, with the same result. (C) Representative electron micrographs of VSMCs in Fibulin-4þ/þ and Fibulin-4R/R
aortas, showing no obvious structural changes, except for smaller mitochondrial size in the latter. The white line indicates a length of 100nm. (D) Representative
western blot for mitochondrial Complexes I–V proteins in Fibulin-4þ/þ and Fibulin-4R/R aorta lysates with b-catenin as loading control. Please note that Complex
IV is lower in size than Complex III. Although detection was done on the same western blot, it is divided into three pieces as the pictures were taken with differ-
ent exposure times; 1, 2, and 5min for b-catenin, Complexes II–V and Complex I, respectively. (E) Quantification of the different complexes for wild-type and
Fibulin-4R/R aortas, showing significant increases in Complexes I–IV in Fibulin-4R/R aortas compared to wild-type (n=4 per genotype, *P<0.05; **P<0.01,
Student’s t-test on log-transformed data). (F) OCR measurements in heart, muscle, and liver, showing lower OCR in Fibulin-4R/R animals compared to their re-
spective Fibulin-4þ/þ littermates (n=3 per genotype, P<0.05, Student’s t-test on log-transformed data). (G) Complex activity measurements in Fibulin-4þ/þ and
Fibulin-4R/R heart and muscle showing no significant difference (n=3 per genotype). All results are expressed as mean± SEM.
10 I. van der Pluijm et al.
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Figure 4 Molecular imaging reveals increased ROS levels in Fibulin-4R/R animals. (A) Representative pictures of three independent experiments show-
ing increased LO12 probe signal intensity (emits light after ROS binding) in Fibulin-4R/R (right) animals compared to respective Fibulin-4þ/þ (left) litter-
mates. (B) Quantification of the average radiance at the site of the aorta, a measure for the amount of ROS reacting with LO12 probe, shows significantly
higher levels in the Fibulin-4R/R compared to Fibulin-4þ/þ mice (n=3 per genotype, *P=0.01, Student’s t-test). (C) Left panel: representative sections of
DHE staining for superoxide anion, in aortic sections from Fibulin-4R/R, counterstained with ethidium for DNA content (red), show increased 2-OH-
DHE fluorescence (green) compared to Fibulin-4þ/þ as shown in the merged picture (left, predominantly green in Fibulin-4R/R vs. yellow in Fibulin-4þ/þ).
The white line indicates a length of 100mm. Right panel: scatter plot depicting the integrated intensity ratio for Fibulin-4þ/þ and Fibulin-4R/R, showing an in-
crease in the latter (n=3 per genotype, *P<0.05, Student’s t-test). All results are expressed as mean± SEM.
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Figure 5 Gene expression analysis and metabolic parameters show altered metabolism in Fibulin-4R/R animals. (A) Graph depicting the top 10 significantly
changed (P<0.01) canonical pathways, derived from an IPA analysis based on the differentially regulated genes between Fibulin-4R/R and Fibulin-4þ/þ aortas,
showing an over-representation of pathways involved in energy metabolism. (B) Scatter plot depicting body weights of Fibulin-4R/R and Fibulin-4þ/þ animals,
showing significant reduction in Fibulin-4R/R compared to Fibulin-4þ/þ animals at 3months (n=38 and 35, respectively, P<0.05, Student’s t-test). (C–E)
Scatter plots depicting glucose (Fibulin-4þ/þ n=6, Fibulin-4R/R n=7), lactate (Fibulin-4þ/þ n=6, Fibulin-4R/R n=5) and ketone levels (Fibulin-4þ/þ n=6,
Fibulin-4R/R n=7), respectively, in blood of Fibulin-4R/R and Fibulin-4þ/þ animals, showing a significant reduction in serum ketone levels for Fibulin-4R/R ani-
mals (P<0.01, Student’s t-test). (F) Representative pictures of oil-red-o staining for lipids in Fibulin-4R/R and Fibulin-4þ/þ livers (left), and quantification of oil-
red-o ratio (right). Compared to their Fibulin-4þ/þ littermates, Fibulin-4R/R show decreased oil-red-o staining in the liver (P<0.01, Student’s t-test) (n=5
per genotype). (G) Representative pictures of PAS staining for glycogen in Fibulin-4R/R and Fibulin-4þ/þ livers (left) and quantification of PAS ratio (right).
Compared to their Fibulin-4þ/þ littermates, Fibulin-4R/R show increased PAS staining in their livers (P<0.01) (n=5 per genotype). The white line indicates a
length of 100mm. All results are expressed as mean± SEM.
12 I. van der Pluijm et al.
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Table 2 Upstream regulator analysis based on IPA gene expression analysis of Fibulin-4R/R vs. Fibulin-4þ/þ aortas.
Upstream
regulator
Description Molecule type Pred.
Act. State
Bias-corrected
z-score
P-value
overlap
FC in
dataset
PPARG Peroxisome proliferator-activated re-
ceptor gamma
Ligand-dependent nuclear
receptor
Inhibited -3.918 4.28E-17 -1.946
SREBF2 Sterol regulatory element binding
transcription factor 2
Transcription regulator Inhibited -3.28 1.74E-11
SCAP SREBF chaperone Other Inhibited -3.212 6.40E-15
ATP7B ATPase, Cuþþ transporting, beta
polypeptide
Transporter Inhibited -3.194 6.94E-07 -1.276
PPARGC1A Peroxisome proliferator-activated re-
ceptor gamma, coactivator 1 alpha
Transcription regulator Inhibited -3.062 8.97E-10 -2.409
SREBF1 Sterol regulatory element binding
transcription factor 1
Transcription regulator Inhibited -3.046 3.10E-15 -1.288
PPARA Peroxisome proliferator-activated re-
ceptor alpha
Ligand-dependent nuclear
receptor
Inhibited -2.968 2.60E-16 -1.720
CTNNA (group) Alpha catenin Group Inhibited -2.946 9.42E-03
NR1H3 Nuclear receptor subfamily 1, group
H, member 3
Ligand-dependent nuclear
receptor
Inhibited -2.904 1.90E-04 -1.522
COL18A1 Collagen, type XVIII, alpha 1 Other Inhibited -2.68 1.79E-01
INSR Insulin receptor Kinase Inhibited -2.509 2.65E-06 -1.268
NR3C1 Nuclear receptor subfamily 3, group
C, member 1 (glucocorticoid
receptor)
Ligand-dependent nuclear
receptor
Inhibited -2.455 7.40E-03
NR1H2 Nuclear receptor subfamily 1, group
H, member 2
Ligand-dependent nuclear
receptor
Inhibited -2.341 9.07E-07
NT5E 5’-Nucleotidase, ecto (CD73) Phosphatase Inhibited -2.328 2.04E-03 1.400
PPARD Peroxisome proliferator-activated re-
ceptor delta
Ligand-dependent nuclear
receptor
Inhibited -2.196 1.16E-04
KLF15 Kru¨ppel-like factor 15 Transcription regulator Inhibited -2.098 5.31E-04
BMP7 Bone morphogenetic protein 7 Growth factor Inhibited -2.094 8.14E-03
HNF4A Hepatocyte nuclear factor 4, alpha Transcription regulator Inhibited -2.072 1.10E-02
PPARGC1B Peroxisome proliferator-activated re-
ceptor gamma, coactivator 1 beta
Transcription regulator Inhibited -2.038 1.19E-06 -1.569
INSIG2 Insulin induced gene 2 Other Activated 2.129 1.10E-09 1.276
FGF19 Fibroblast growth factor 19 Growth factor Activated 2.13 6.29E-05
NRIP1 Nuclear receptor interacting protein
1
Transcription regulator Activated 2.185 4.81E-12
HOXC6 Homeobox C6 Transcription regulator Activated 2.219 4.30E-02 -1.411
KRT17 Keratin 17 Other Activated 2.468 8.52E-03
PTGS2 Prostaglandin-endoperoxide synthase
2
Enzyme Activated 2.505 2.35E-01 1.618
LTa1b2 Lymphotoxin-alpha1-beta2 Complex Activated 2.546 1.01E-03
SPI1 Spleen focus forming virus (SFFV)
proviral integration oncogene spi1
Transcription regulator Activated 2.632 1.44E-02 1.621
PI3K (complex) Phosphatidylinositol 3-kinase Complex Activated 2.65 9.19E-02
WNT1 Wingless-type MMTV integration site
family, member 1
Cytokine Activated 2.708 3.01E-03
OSM Oncostatin M Cytokine Activated 2.708 1.99E-04
POR P450 (cytochrome) oxidoreductase Enzyme Activated 2.723 5.04E-07 -1.626
SPP1 Secreted phosphoprotein 1 Cytokine Activated 2.748 7.42E-06 4.884
RET Ret proto-oncogene Kinase Activated 2.772 6.63E-04
Continued
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P<0.05, n=11, and n=7, respectively), whereas levels of PPARa and
PPARc were lower but not significantly different from Fibulin-4þ/þ
(Supplementary material online, Figure S4C). Interestingly, in the liver we
found that PGC1awas significantly upregulated (Supplementary material
online, Figure S4D, P<0.05), which would be consistent with the ob-
served lower lipid content (higher lipid usage) of the liver (Figure 5F) and
the somewhat higher OCR (Figure 3G). PGC1a is the master switch be-
tween mitochondrial biogenesis and organismal metabolism, and signals
to PPARs, essential regulators of lipid metabolism, making these interest-
ing molecules for further investigation. Moreover, when examining the
networks predicted to be significantly regulated in our gene expression
dataset, the highest significantly regulated network is ‘Energy
Production/Lipid Metabolism/Small Molecule Biochemistry’
(Supplementary material online, Figure S3). The visual representation of
this network, derived from IPA, highlights that PPARa and PPARc play a
central role (Supplementary material online, Figure S6A).
Next, we performed a gene to protein comparison, where we com-
pared the lists of significantly regulated genes and proteins in adult
Fibulin-4R/R aortas to Fibulin-4þ/þ. This comparison revealed 30 mole-
cules that changed both at the gene and protein level (Supplementary
material online, Figure S6B). This list included key genes/proteins involved
in metabolism, like glucose-6-phosphate dehydrogenase and fatty acid
synthase (Supplementary material online, Figure S6B). Strikingly, when
we asked whether IPA could find a connection between the 30 overlap-
ping molecules (core analysis on the 30 genes/proteins in common), we
indeed found the highest network regulated to be Lipid Metabolism, in
which again PPARa and PGC1a are involved as key regulators
(Supplementary material online, Figure S6C).
In order to check PGC1a activity in VSMCs, we used a luciferase-
based assay. We transfected plasmids containing firefly luciferase under
the control of the PGC1a promoter in Fibulin-4R/R and Fibulin-4þ/þ
VSMCs, with plasmids containing renilla luciferase as transfection con-
trol. Relative luciferase levels, a measure for PGC1a activity, were
significantly lower in Fibulin-4R/R VSMCs (Figure 6B, P<0.01). It was
reported that TGFb signalling negatively regulates PGC1a.33,34 As we
previously found TGFb signalling to be increased in Fibulin-4R/R aortas
and cells,13,31 we next investigated the effect of TGFb signalling on
PGC1a. We performed the PGC1a luciferase-based assay on Fibulin-
4þ/þ and Fibulin-4R/R VSMCswith either TGFb treatment, TGFbR inhibi-
tion (SB431542), or Forskolin, a potent inducer of PGC1a activity. In
both Fibulin-4þ/þ and Fibulin-4R/R VSMCs, treatment with TGFb signifi-
cantly reduced PGC1a transcription (Figure 6C, P<0.01), showing that
also in VSMCs TGFb signalling negatively regulates PGC1a. Yet, TGFbR
inhibition did not significantly increase PGC1a activation, pointing to the
involvement of non-canonical TGFb signalling as SB431542 does not in-
hibit JNK, p38MAPK, or ERK signalling. Forskolin significantly induced
PGC1a activity in both Fibulin-4R/R and Fibulin-4þ/þ VSMCs (Figure 6C,
P<0.01); in both cases a three-fold induction compared to the untreated
situation. These data point to an active inhibition of PGC1a activity in
VSMCs of Fibulin-4R/R aortas. We next performed seahorse experi-
ments in which we either examined the effect of TGFbR inhibition, or
PGC1a activation. Interestingly, activation of PGC1a increased basal and
maximum oxygen consumption in both Fibulin-4þ/þ and Fibulin-4R/R
VSMCs (Figure 6D, P<0.05), whereas TGFbR inhibition did not have the
same effect. It was previously found that Fibulin-4R/R VSMCs show low
proliferation rates compared to Fibulin-4þ/þ VSMCs, which can be res-
cued by inhibiting TGFb.31 As TGFb negatively regulates PGC1a levels,
we examined whether increased PGC1a levels would also rescue this
low proliferation rate. Indeed, PGC1a activation was able to significantly
increase the proliferation rate of Fibulin-4R/R VSMCs specifically (Figure
6E, P<0.01). Taken together, these results show that PGC1a, an impor-
tant molecular switch between mitochondrial biogenesis and organismal
metabolism, is downregulated in aortas of Fibulin-4R/R animals due to in-
creased TGFb signalling. When activated, PGC1a can restore the de-
crease in oxygen consumption and the decreased proliferation in
Fibulin-4R/R VSMCs.
..............................................................................................................................................................................................................................
Table 2 Continued
Upstream
regulator
Description Molecule type Pred.
Act. State
Bias-corrected
z-score
P-value
overlap
FC in
dataset
CSF2 Colony stimulating factor 2 (granulo-
cyte-macrophage)
Cytokine Activated 2.797 1.04E-03 1.236
MAP3K1 Mitogen-activated protein kinase 1,
E3 ubiquitin protein ligase
Kinase Activated 2.802 5.06E-04
IL18 Interleukin 18 (interferon-gamma-in-
ducing factor)
Cytokine Activated 2.938 5.40E-02
TNFRSF1A Tumour necrosis factor receptor su-
perfamily, member 1A
Transmembrane receptor Activated 2.956 4.40E-02
NFkB (complex) Nuclear factor of kappa light poly-
peptide gene enhancer in B-cells
Complex Activated 3.064 1.50E-02
FOXO1 Forkhead box O1 Transcription regulator Activated 3.278 9.93E-13 -1.419
TNF Tumour necrosis factor Cytokine Activated 3.842 1.78E-06
MYD88 Myeloid differentiation primary re-
sponse gene (88)
Other Activated 3.857 3.54E-03
IL1A Interleukin 1, alpha Cytokine Activated 4.315 9.91E-05
IFNG Interferon, gamma Cytokine Activated 4.527 2.64E-02
The upstream regulator abbreviation, its description, type of molecule, predicted activation state (activated or inhibited), bias-corrected z-score, p-value and are shown. Also, if the
upstream regulator is significantly regulated at the gene expression level in our gene expression dataset, fold changes are depicted. Upstream regulators with an unbiased z-score
>2 or < -2, and significant p-value <0.01 are depicted.
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Figure 6 PGC1a expression and activity changes in Fibulin-4R/R aortas and VSMCs. Real-time PCR analysis shows significantly downregulated mRNA lev-
els of PGC1a and PGC1b in Fibulin-4R/R compared to Fibulin-4þ/þ aortas (P<0.05, n=7, and n=11, respectively, Student’s t-test on log-transformed data).
(B) Relative luciferase levels show decreased PGC1a transcriptional activation in Fibulin-4R/R compared to Fibulin-4þ/þ VSMCs (P<0.01, Student’s t-test on
log-transformed data). (C) Relative luciferase levels show decreased PGC1a transcriptional activation after TGFb treatment in both Fibulin-4R/R (right) and
Fibulin-4þ/þ (left) VSMCs compared to the untreated (NT) control. Forskolin, a potent PGC1a activator, significantly increases PGC1a transcriptional acti-
vation in both Fibulin-4R/R and Fibulin-4þ/þ VSMCs to the same extent as compared to the untreated control. Data are shown for three independent experi-
ments, n=3 cell lines per genotype. TGFb inhibition does not significantly increase PGC1a activity. (D) Scatter plots depicting the basal and maximum
oxygen consumption rate (OCR) in Fibulin-4þ/þ and Fibulin-4R/R VSMCs after Forskolin treatment, which activates PGC1a, compared to the untreated con-
trols, and TGFb inhibition. Both Fibulin-4þ/þ and to Fibulin-4R/R show a significant increase in basal and maximumOCR compared to the untreated controls
(P<0.01, Student’s t-test) after Forskolin treatment. TGFb inhibition does not show a significant increase. Experiments were performed twice, n=2 cell lines
Reduced mitochondrial respiration in Fibulin-4 mice 15
Downloaded from https://academic.oup.com/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvy150/5042174
by University of Sheffield user
on 09 August 2018
..
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
4. Discussion
In this study, we took an integrative approach to better understand the
molecular mechanisms involved in aneurysm formation, by using a com-
bination of proteomics, genomics and functional experiments on tho-
racic aortas of aneurysmal Fibulin-4R/R animals. Interestingly, these data
indicated changes in mitochondrial function and energy metabolism.
Indeed, we measured a decrease in OXPHOS in VSMCs derived from
the thoracic aorta of Fibulin-4R/R and Fibulin-4þ/þ animals. In addition,
we observed smaller mitochondria, but not less mitochondria or lower
activity of mitochondrial complexes. Furthermore, in Fibulin-4R/R com-
pared to Fibulin-4þ/þ mice, we observed aortic gene expression differ-
ences that indicated altered aortic metabolic processes. Upstream
regulator analysis on gene and protein expression data indicated
PGC1a, PPARa, and PPARc as significant regulators in this process.
Moreover, we found that PGC1a transcriptional activation was greatly
reduced in VSMCs derived from Fibulin-4R/R aortas, and once PGC1a
was activated in these VSMCs, this restored the decreased OCR ob-
served in Fibulin-4R/R VSMCs as well as their reduced growth rate.
We verified that the observed defect in mitochondrial function was
due to reduced Fibulin-4 in Fibulin-4R/R cells, rather than potential sec-
ondary effects associated with the engineered allele; to this end, we used
the Fibulin-4SMKO mouse model as a control, in which the Fibulin-4 gene
is completely knocked out in VSMCs specifically. Indeed, these Fibulin-
4SMKO VSMCs showed a diminished OCR, as we observed for Fibulin-
4R/R VSMCs, showing that complete deletion of Fibulin-4 has a similar ef-
fect on mitochondrial respiration as the Fibulin-4 reduced allele.
Although very little data are available on involvement of mitochondria
in aneurysm formation and development, some evidence points in this
direction. For example, mutations in SLC2A10 result in Arterial
Tortuosity Syndrome (ATS, OMIM#208050,35) a connective tissue dis-
order characterized by elongation and tortuosity of the major arteries
including the aorta. SLC2A10 encodes for GLUT10, a glucose transporter
that transports l-dehydro ascorbic acid (DHA) into mitochondria. The
absence of GLUT10 leads to decreased DHA recycling and thus to
more oxidative damage. In zebrafish, defects in this gene lead to prob-
lems in development of the cardiovascular system in parallel to mito-
chondrial dysfunction.36 In line with this notion, we demonstrate that
VSMCs from the Tgfbr-1M318R/þ mouse, a model for LDS,28 similarly
show reduced OCR. Moreover, we find that Marfan and Loeys-Dietz pa-
tient fibroblasts with mutations in the FBN1, TGFBR2, and SMAD3 genes
also show reduced OCR. These observations support the concept that
altered mitochondrial function plays a role in aneurysmal disease.
An important question is how a deficiency in a protein involved in
structural integrity of the ECM can lead to altered mitochondrial func-
tion and metabolism. External cues can lead to cytoskeleton rearrange-
ments since the ECM is connected to the cytoskeleton via integrins.
Alternatively, ECM disturbances could invoke alterations in mechano-
transduction that lead to modifications in the cytoskeleton or maybe
even to its disintegration. Mitochondria depend on the cytoskeleton for
their motility and proper function (for review see reference 37). Thus, if
the ECM disintegrates, this could lead to cytoskeleton disintegration due
to loss of connections. In turn, this could lead to structural or functional
defects in mitochondria. In fact, several genes that are components of
the cytoskeleton are mutated in aneurysmal disease, exemplifying that
the cytoskeleton is an important factor. One example is ACTA2, encoding
aSMA, which is a major constituent of the contractile apparatus, that
when mutated, leads to ascending aortic aneurysms and dissection
(AAT6, OMIM##61178838). However, although we did observe mito-
chondrial function changes and a reduction in mitochondrial size, mito-
chondrial structure and appearance did not seem to be affected. Also,
mitochondria are still aligned along the actin cytoskeleton as could be in-
ferred from EM pictures and stainings for actin.
In addition, Fibulin-4R/R mice show increased TGFb signalling.
Notably, several papers recently reported that TGFb signalling negatively
regulates PGC1a levels.33,34 Interestingly, derived from our omics data,
PGC1a, PPARa, and c were identified as key components in the mito-
chondrial biogenesis signalling process. PGC1a is a transcriptional co-
activator and is expressed in tissues with high oxidative capacity, where
it serves important roles in regulation of mitochondrial functional capac-
ity and cellular energy metabolism.39 Physiological conditions that de-
mand increased mitochondrial energy production, such as exercise and
fasting, induce PGC1a activity. Likewise, low PGC1a levels imply re-
duced mitochondrial function. Accordingly, studies on PGC1a deficient
(PGC1a-/-) mice have shown that PGC1a is necessary for regulation of
mitochondrial function and cellular metabolism.40 Both mitochondrial
volume density and respiratory capacity are reduced in these mice and
there is no normal control of body fat mass, which emphasizes the im-
portance of PGC1a in fatty acid b-oxidation. Furthermore, PGC1a-/-
mice do not respond normally to increased demands for energy.40
PGC1a is involved in the mitochondrial oxidation of fatty acids for en-
ergy in the cell through direct co-activation of PPARs.39 Recently it was
shown that PGC1a protein expression is also lowered in aortic material
isolated from patients with abdominal aneurysms,41 which indicates that
PGC1a expression may play a regulatory role in both thoracic and ab-
dominal aneurysms.41 Moreover, increasing mitochondrial function via
PGC1a activation has a positive effect on aging and longevity.42,43
Interestingly, we not only found lower PGC1a expression in Fibulin-4R/R
thoracic aortas but also PGC1a transcriptional activation itself was
down in Fibulin-4R/R VSMCs. However, this activation could be en-
hanced by Forskolin, a PGC1a activator, and enhancement of PGC1a
activation was able to restore the decreased oxidative respiration ob-
served in Fibulin-4R/R VSMCs.
We also found that TGFb decreased PGC1a transcriptional levels in
Fibulin-4þ/þ and Fibulin-4R/R VSMCs, implying that the increased TGFb
signalling in Fibulin-4R/R aortas and VSMCs is responsible for the de-
creased PGC1a levels, thus impacting mitochondrial respiration. This
would also explain why we find reduced mitochondrial respiration in
cells derived from other aneurysmal syndromes that show increased
TGFb signalling, such as LDS and Marfan. Ramnath et al.31 showed that
lowering of TGFb levels in Fibulin-4R/R VSMCs restored their reduced
proliferation rate. Similarly, we now show that by activating PGC1a, we
Figure 6 Continued
per genotype. (E) Growth curves of Fibulin-4R/R and Fibulin-4þ/þ VSMCs showing that activation of PGC1a significantly restores the reduced
growth of Fibulin-4R/R VSMCs compared to the untreated situation (NT) (P<0.01, non-linear fit of exponential decay). Experiments were per-
formed twice, n=2 cell lines per genotype, the mean of two cell lines is shown. All results are expressed as mean± SEM.
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can also increase this proliferation rate, suggesting that this reduced pro-
liferation phenotype is induced by increased TGFb levels, possibly via
PGC1a reduction.
It is evident that mitochondria are major cellular sources of ROS and
changes in metabolism can alter mitochondrial function and the resulting
ROS production. Likewise, in Fibulin-4R/R animals, we find evidence for
increased ROS in the aorta. In this regard, changes in mitochondrial me-
tabolism could also be an attempt to adapt to increased ROS, or to re-
duce ROS in response to a potential source of damage, at the organismal
level. In line with this, we also find reduced oxygen consumption in other
muscle cell containing organs; heart and skeletal muscle, but not in kid-
ney or liver. Furthermore, in Fibulin-4R/R animals we observe a relative
shift from glucose utilization to fatty acid usage as evidenced from meta-
bolic parameters in blood and liver, as well as from our aortic gene ex-
pression analysis. The accumulation of glycogen in the liver might
indicate increased storage of glucose into glycogen, in accordance to a
relative increase in fatty acid b-oxidation that provides the energy for
gluconeogenesis in the absence of an increased demand for glucose from
the liver. Interestingly, newborn livers do not yet show these changes in
liver metabolism. However, they do already show aneurysms, which
may indicate that the aortic structural and/or signalling changes induce
the liver metabolic changes at a later stage. The observed metabolic
changes in adult Fibulin-4R/Rmice are even more interesting since we did
not detect changes in the liver mitochondrial complexes themselves, but
did observe upregulation of PGC1a mRNA levels, pointing to a normal
response of the liver to a change in demand of energy carrier type.
Plasma measurements of Fibulin-4R/Rmice show significantly lower levels
of ketone bodies compared to their wild-type littermates. Taken to-
gether, this could indicate that the thoracic aorta of Fibulin-4R/R mice
retrieves its energy from ketone bodies rather than from glucose, which
could be the underlying reason for the liver to switch from glucose to
fatty acid usage. In fact, adapting organismal metabolism under conditions
of stress, such as organ damage, is a well-known survival mechanism in
aging that attempts to preserve the organism by allowing time and en-
ergy for repair.44,45 Actually, mitochondrial dysfunction itself is consid-
ered an important hallmark of aging.46 ROS and mitochondrial
dysfunction both increase with age, resulting in decreased bioenergetic
efficiency. In fact, age-related aneurysms show many vascular aging char-
acteristics such as elastin breakdown, collagen deposition as well as mor-
phological changes in VSMCs.47 Previously, we identified similar
overexpression of miR-29b in Fibulin-4R/R aneurysmal aortas and aging
mouse aortas, concomitant with reduced ECM protein expression
thereby sensitizing the aorta for aneurysms formation.32 In line with this,
structural ECM changes could induce signalling processes that are partly
mediated by TGFb, including those involving mitochondrial biogenesis.
These signalling responses would then attempt to reduce aortic damage,
similar to the organismal response observed in aging.
In this context, it would be interesting to see the effect of PGC1a acti-
vators on aneurysm formation in the Fibulin-4R/R mouse. Previously, calo-
rie restriction has been shown to have positive effects on mitochondrial
biogenesis as well as many aging characteristics in different species48,49 and
notably also affects PGC1a signalling by increasing PGC1a. In line with
this, the results reported here could open up the exciting possibility of nu-
tritional interventions as a possible treatment for aneurysmal disease.
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Supplementary material is available at Cardiovascular Research online.
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